Home » USA Broker Ratings » Neurocrine Biosciences, Inc. – Consenus Indicates Potential 15.1% Upside

Neurocrine Biosciences, Inc. – Consenus Indicates Potential 15.1% Upside

Neurocrine Biosciences, Inc. with ticker code (NBIX) now have 18 analysts in total covering the stock. The consensus rating is ‘Buy’. The target price ranges between 130 and 93 and has a mean target at 111.44. With the stocks previous close at 96.85 this would indicate that there is a potential upside of 15.1%. There is a 50 day moving average of 94.33 while the 200 day moving average is 88.07. The market capitalisation for the company is $8,771m. Find out more information at: http://www.neurocrine.com

Neurocrine Biosciences, Inc. discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company offers INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2), which is used for the treatment of movement disorders; ORILISSA, a gonadotropin-releasing hormone (GnRH) antagonist for use in women’s health. Its product candidates in clinical development include elagolix that is in Phase III clinical trial for Uterine Fibroids; opicapone, a catechol-O-methyltransferase inhibitor, which is in Phase III clinical trial that is used for in adjunct therapy and preparations of levodopa/DOPA decarboxylase inhibitors for adult patients with Parkinson’s disease; and NBI-74788, which is in Phase II clinical trial for the treatment of congenital adrenal hyperplasia. The company’s product candidates also comprise VMAT2 Inhibitors and which are in Phase I clinical trial for neurology/psychiatry disorders. It has collaborations and agreements with AbbVie Inc. to develop and commercialize elagolix and GnRH antagonists for women’s and men’s health; Mitsubishi Tanabe Pharma Corporation to develop and commercialize INGREZZA for movement disorders; and BIAL – Portela & Ca, S.A. to develop and commercialize opicapone for the treatment of human diseases and conditions, including Parkinson’s disease. The company also has a research collaboration agreement with Jnana Therapeutics Inc. to discover novel small molecule therapeutics for multiple targets for central nervous system disorders; and a collaboration and license agreement with Voyager Therapeutics, Inc. for the research, development, and commercialization of VY-AADC program for Parkinson’s disease and VY-FXN01 program for Friedreich’s ataxia. Neurocrine Biosciences, Inc. was founded in 1992 and is headquartered in San Diego, California.